| 000 | 01723 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250514184357.0 | ||
| 264 | 0 | _c20050126 | |
| 008 | 200501s 0 0 eng d | ||
| 022 | _a0033-3158 | ||
| 024 | 7 |
_a10.1007/s00213-004-1852-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrankle, W G | |
| 245 | 0 | 0 |
_aOccupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications. _h[electronic resource] |
| 260 |
_bPsychopharmacology _cOct 2004 |
||
| 300 |
_a473-80 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAlgorithms |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xmetabolism |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aBenzodiazepines _xpharmacology |
| 650 | 0 | 4 |
_aDopamine _xmetabolism |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOlanzapine |
| 650 | 0 | 4 | _aPsychiatric Status Rating Scales |
| 650 | 0 | 4 | _aPyrrolidines |
| 650 | 0 | 4 | _aRadiopharmaceuticals |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xmetabolism |
| 650 | 0 | 4 |
_aRisperidone _xpharmacology |
| 650 | 0 | 4 |
_aSchizophrenia _xdiagnostic imaging |
| 650 | 0 | 4 | _aTomography, Emission-Computed, Single-Photon |
| 700 | 1 | _aGil, R | |
| 700 | 1 | _aHackett, E | |
| 700 | 1 | _aMawlawi, O | |
| 700 | 1 | _aZea-Ponce, Y | |
| 700 | 1 | _aZhu, Z | |
| 700 | 1 | _aKochan, L D | |
| 700 | 1 | _aCangiano, C | |
| 700 | 1 | _aSlifstein, M | |
| 700 | 1 | _aGorman, J M | |
| 700 | 1 | _aLaruelle, M | |
| 700 | 1 | _aAbi-Dargham, A | |
| 773 | 0 |
_tPsychopharmacology _gvol. 175 _gno. 4 _gp. 473-80 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00213-004-1852-4 _zAvailable from publisher's website |
| 999 |
_c14796768 _d14796768 |
||